Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa

Sep 28, 2026, 9:34 AM

Read Full Article → Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa

Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa

Translate article text

Choose a language and wait for the translated text.

Novo has meanwhile been busy bolstering its pipeline amid a target to launch more than five multi-blockbusters by 2030.

Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa | PharmaVoice